- Verastem (VSTM +1.7%) is initiated with a Buy rating at Jefferies. Price target is $21, representing a 42% upside from Friday's close.
- Analyst Biren Amin says VS-6063 "has favorable odds of showing a PFS benefit [in mesothelioma trials], supporting potential accelerated approval in H2 2016."
- For more on VS-6063, see previous coverage.
Jefferies starts Verastem at Buy
Jul 29 2013, 11:24 ET